ArticleInflammopharmacology2025
Gut microbiome-targeted therapeutics for chronic kidney disease: comparative efficacy of probiotic and microbial preparations.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence of fluoroquinolone resistance inFrontiers in cellular and infection microbiology · 2026Pooled it
- Gut‑liver‑kidney axis: A systems biology framework for understanding and treating chronic kidney disease (Review).International journal of molecular medicine · 2026Review
- Aloin attenuates high-glucose-induced oxidative and inflammatory damage in renal cells via AMPK/Nrf2 signaling.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Supplementation with the probiotic Bifidobacterium lactis BB-12 improves the efficacy of alendronate sodium/vitamin D₃ therapy on skeletal health in stage 3 CKD.Journal of endocrinological investigation · 2026Article
- Early-Life Iron Exposure Influences Long-Term Gut Microbiota Recovery After Intestinal Dysbiosis.Microorganisms · 2026Article
- Mucuna pruriens extract as prebiotic and Lactobacillus rhamnosus as probiotic intervention mitigated histological changes in DNCB-induced colitis via GLP-1/Nrf2/NF-κB axis regulation.Journal of molecular histology · 2026Article
- Precision Microbial Therapeutics for Infertility: Next-Generation Probiotics, Engineered Biologics and Translational Pathways.Microbial biotechnology · 2026Review
- Age-Specific Association Between the Dietary Inflammatory Index and Depression Among Patients With Chronic Kidney Disease.Food science & nutrition · 2026Article
- Early Detection of Chronic Kidney Disease in Men Using Lifestyle and Demographic Indicators: A Machine Learning Approach for Primary Healthcare Settings.Healthcare (Basel, Switzerland) · 2026Article
- Gut-Kidney Axis: Unraveling the Role of the Microbiome in Chronic Kidney Disease.Biomedicines · 2026Review
- The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.Acta biochimica Polonica · 2026Review
- Alterations in gut microbiota among maintenance hemodialysis patients with CKD-associated pruritus: a cross-sectional comparative study of two cohorts.Frontiers in cellular and infection microbiology · 2026Article
- Molecular immunopharmacology of traditional Chinese medicine-derived compounds in membranous nephropathy: mechanistic insights into immune aging and kidney essence deficiency.Frontiers in immunology · 2026Review
- Bidirectional Communication of the Gut-Brain Axis in Pain Regulation: From Microbial Metabolites to Neuroinflammation.Journal of inflammation research · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundProbiotics supplements may be a solution to improve and delay chronic kidney disease (CKD), but their anti-inflammatory and other effects remain unclear. Our study conducted network meta-analysis (NMA) to appraise the efficacy of supplementary probiotic and microbial preparations for CKD patients.
methodsSearches for eligible trials were performed until January 30, 2025. The relative efficacy of various interventions was assessed using surface under the cumulative ranking (SUCRA).
resultsThis NMA included 53 studies and evaluated 4 aspects of the outcomes: renal markers and uremic toxins, glucolipid metabolism, inflammation and oxidative stress indices, and dietary intake. Multi-combination of three probiotics (Mix1) and four or more probiotics (Mix2) intervention were associated with significantly higher efficacy. For example, Mix2 intervention was the highest effecacy in reducing creatinine (SUCRA: 79.1%) and glucose (SUCRA: 97.1%). Moreover, Mix1 yielded the best ranking in decreasing uric acid (SUCRA: 82.5%), fasting blood sugar (FBS) (SUCRA: 92.0%), and malondialdehyde (MDA) (SUCRA: 78.7%).
conclusionMulti-combination of three or more probiotics may be the best choice for improving renal function, glucolipid metabolism, inflammation, oxidative stress, and dietary intake in CKD patients.
Indexed as
Identifiers
41236711What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.